A citation-based method for searching scientific literature

David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoine Italiano, Ralf-Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schuler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzen, Maria Luisa Veronese, Josep Tabernero, José Baselga. N Engl J Med 2015
Times Cited: 1045







List of co-cited articles
895 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
30

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
437
20

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
18

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L Beijersbergen, Alberto Bardelli, René Bernards. Nature 2012
17

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Scott Kopetz, Jayesh Desai, Emily Chan, Joel Randolph Hecht, Peter J O'Dwyer, Dipen Maru, Van Morris, Filip Janku, Arvind Dasari, Woonbook Chung,[...]. J Clin Oncol 2015
382
17

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, Erin M Coffee, Michiya Nishino, Alexandria P Cogdill, Ronald D Brown, Patricia Della Pelle, Dora Dias-Santagata, Kenneth E Hung,[...]. Cancer Discov 2012
624
15

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
15

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
14

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
385
13

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Ryan B Corcoran, Thierry André, Chloe E Atreya, Jan H M Schellens, Takayuki Yoshino, Johanna C Bendell, Antoine Hollebecque, Autumn J McRee, Salvatore Siena, Gary Middleton,[...]. Cancer Discov 2018
264
13

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
12

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
361
12

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
12

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh,[...]. Br J Cancer 2019
146
11

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
11

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
664
10


The consensus molecular subtypes of colorectal cancer.
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino,[...]. Nat Med 2015
10

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.
Robin M J M van Geel, Josep Tabernero, Elena Elez, Johanna C Bendell, Anna Spreafico, Martin Schuler, Takayuki Yoshino, Jean-Pierre Delord, Yasuhide Yamada, Martijn P Lolkema,[...]. Cancer Discov 2017
122
10

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
236
10

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
406
10

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim,[...]. N Engl J Med 2012
9

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Scott Kopetz, Katherine A Guthrie, Van K Morris, Heinz-Josef Lenz, Anthony M Magliocco, Dipen Maru, Yibing Yan, Richard Lanman, Ganiraju Manyam, David S Hong,[...]. J Clin Oncol 2021
42
21

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
449
9

Genomic spectra of biliary tract cancer.
Hiromi Nakamura, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi,[...]. Nat Genet 2015
571
8

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Milind Javle, Maeve Lowery, Rachna T Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J Borad, Ramesh K Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla,[...]. J Clin Oncol 2018
302
8

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019
387
8

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
652
8

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent-Puig,[...]. Lancet Oncol 2010
8

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
E Van Cutsem, A Cervantes, R Adam, A Sobrero, J H Van Krieken, D Aderka, E Aranda Aguilar, A Bardelli, A Benson, G Bodoky,[...]. Ann Oncol 2016
8

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
Rona Yaeger, Andrea Cercek, Eileen M O'Reilly, Diane L Reidy, Nancy Kemeny, Tamar Wolinsky, Marinela Capanu, Marc J Gollub, Neal Rosen, Michael F Berger,[...]. Clin Cancer Res 2015
181
8

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
David S Hong, Van K Morris, Badi El Osta, Alexey V Sorokin, Filip Janku, Siqing Fu, Michael J Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee,[...]. Cancer Discov 2016
142
8

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
218
8

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W Prager, Richard Greil, Alexander Stein,[...]. Lancet Oncol 2020
91
8

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
494
8

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
8

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
412
8

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
248
8

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
343
7

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Lipika Goyal, Lei Shi, Leah Y Liu, Ferran Fece de la Cruz, Jochen K Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W S Ng,[...]. Cancer Discov 2019
132
7

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I Shapiro, Dejan Juric, David I Quinn, Victor Moreno, Bernard Doger,[...]. Nature 2018
349
7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
7

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni,[...]. Lancet Oncol 2015
525
7

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
Ben Tran, Scott Kopetz, Jeanne Tie, Peter Gibbs, Zhi-Qin Jiang, Christopher H Lieu, Atin Agarwal, Dipen M Maru, Oliver Sieber, Jayesh Desai. Cancer 2011
453
7

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
7

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
181
7

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Jeffrey S Ross, Kai Wang, Laurie Gay, Rami Al-Rohil, Janne V Rand, David M Jones, Hwa J Lee, Christine E Sheehan, Geoff A Otto, Gary Palmer,[...]. Oncologist 2014
272
7

Biliary cancer: Utility of next-generation sequencing for clinical management.
Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C Kang, Daniel Catenacci, Siraj Ali, Sunil Krishnan,[...]. Cancer 2016
163
7

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
327
7

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N Primrose, Richard P Fox, Daniel H Palmer, Hassan Z Malik, Raj Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones,[...]. Lancet Oncol 2019
371
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.